UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

European Journal of Cancer 2024 March 1 [Link] Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland Abstract Purpose: The NIPU-trial investigates the effect of adding the telomerase vaccine…

Read More

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma

Cancer Genomics & Proteomics 2024 March-April [Link] Daiki Shimizu, Miku Ishibashi, Tadaaki Yamada, Yuki Toda, Shigekuni Hosogi, Eishi Ashihara Abstract Background/aim: The prognosis of patients with malignant pleural mesothelioma (MPM) remains poor due to lack of effective therapeutic targets. DNA damage caused by long-time exposure to asbestos fibers has been associated with the development of…

Read More

Successful treatment of simultaneous malignant pleural mesothelioma and pulmonary adenocarcinoma: A case report

Oncology Letters 2024 February 15 [Link] Yuki Amakusa, Tatsuro Suzuki, Yu Hikosaka, Masaya Takemura, Tetsuya Oguri Abstract The present report described the case of a 74-year-old male patient with asbestos exposure whose chest computed tomography revealed a right lower lobe nodule and right pleural effusion. Pleural biopsy led to the diagnosis of epithelial malignant pleural…

Read More

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

Translational Oncology 2024 May [Link] Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti Abstract Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly…

Read More

The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review

Journal of Thoracic Disease 2024 January 30 [Link] Maria Teresa Congedo, Elizabeth Casey West, Jessica Evangelista, Aubrey Anne Mattingly, Giuseppe Calabrese, Carolina Sassorossi, Adriana Nocera, Marco Chiappetta, Sara Flamini, Ludovico Abenavoli, Stefano Margaritora, Luigi Boccuto, Filippo Lococo Abstract Background and objective: Malignant pleural mesothelioma (MPM) is a very aggressive primary tumor of the pleura whose…

Read More

CHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma

International Journal of Molecular Sciences 2024 February 14 [Link] Shoji Okado, Taketo Kato, Yuki Hanamatsu, Ryo Emoto, Yoshito Imamura, Hiroki Watanabe, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tamotsu Takeuchi, Shigeyuki Matsui, Toyofumi Fengshi Chen-Yoshikawa Abstract Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this…

Read More

The Impact of 3D Nichoids and Matrix Stiffness on Primary Malignant Mesothelioma Cells

Genes 2024 February 1 [Link] Stefania Oliveto, Paolo Ritter, Giorgia Deroma, Annarita Miluzio, Chiara Cordiglieri, Mauro Roberto Benvenuti, Luciano Mutti, Manuela Teresa Raimondi, Stefano Biffo Abstract Malignant mesothelioma is a type of cancer that affects the mesothelium. It is an aggressive and deadly form of cancer that is often caused by exposure to asbestos. At…

Read More

Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes

Current Oncology 2024 February 14 [Link] Andrew Baird, Abdullah Nasser, Peter Tanuseputro, Colleen Webber, Paul Wheatley-Price, Camille Munro Abstract Malignant pleural mesothelioma is a rare, aggressive, and incurable cancer with a poor prognosis and high symptom burden. For these patients, little is known about the impact of palliative care consultation on outcomes such as mortality,…

Read More

Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk

Annals of Surgical Oncology 2024 February 19 [Link] Varun V Bansal, Owen Mitchell, Celyn Bregio, Hunter D D Witmer, Ankit Dhiman, Frederick A Godley 4th, Cecilia Ong, Yaniv Berger, Biren Reddy, Jane E Churpek, Michael W Drazer, Oliver S Eng, Hedy L Kindler, Kiran K Turaga Abstract Introduction: Venous thromboembolism (VTE) is a common complication…

Read More